🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Edinburgh
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Edinburgh

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 675 Birmingham 472 Glasgow 439 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca34 Merck Sharp & Dohme LLC15 Janssen Research & Development, LLC13 AbbVie10 Hoffmann-La Roche9
Site city
London2010 Manchester675 Birmingham472 Glasgow439 Cambridge416
All 426 cities
Target enrolment
to
252 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
Bristol-Myers Squibb
Phase 3
586
Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield
2025-07-21
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
140
Edinburgh, Glasgow, London, Cardiff, Manchester
2025-07-20
Active, closed
A Study to Assess THN391 in Subjects With Alzheimer's Disease
NCT06814730Alzheimer Disease, Early Onset
Therini Bio, Inc.
Phase 1
19
Edinburgh, London
2025-07-17
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Amgen
Phase 2
220
Cambridge, Edinburgh, Leicester, Newcastle upon Tyne
2025-07-16
Recruiting
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494Early Alzheimer's Disease
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Not yet open
Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
NCT05647096Sepsis, Respiratory Failure
Santersus AG
Not applicable
73
Birmingham, Edinburgh, Liverpool, London
2025-07-01
Active, closed
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
NCT06794554Chronic Pulmonary Aspergillosis
Mundipharma Research Limited
Phase 2
60
Cambridge, Derby, Dundee, Edinburgh, Leeds, London, Manchester
2025-06-30
Active, closed
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
NCT06736990Idiopathic Pulmonary Fibrosis
Calluna Pharma AS
Phase 2
150
Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton
2025-06-20
Recruiting
Bladder EpiCheck European Haematuria Study
NCT06818136Hematuria, Cystoscopy, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Nucleix Ltd.
Observational
800
Dunfermline, Cambridge, Edinburgh, London, Surrey Quays
2025-06-20
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
BioNTech SE
Phase 3
480
Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London
2025-06-10
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 3
600
Brighton, Cambridge, Canterbury, Colchester, Edinburgh, Liverpool, London, Plymouth
2025-06-04
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
1,123
East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester
2025-05-22
Recruiting
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805Idiopathic Pulmonary Fibrosis
Mediar Therapeutics
Phase 2
164
Birmingham, Cambridge, Edinburgh, Oxford
2025-05-05
Recruiting
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248Multiple Sclerosis
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
Hoffmann-La Roche
Phase 3
450
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
2025-04-09
Active, closed
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
NCT06738017Alpha 1-Antitrypsin Deficiency
BioMarin Pharmaceutical
Phase 1
6
Edinburgh, London, Southampton
2025-02-21
Recruiting
Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis
NCT06487273Non-cystic Fibrosis Bronchiectasis
Physio-Assist
Not applicable
622
Belfast, Birmingham, Edinburgh, Manchester, Newcastle upon Tyne
2025-02-03
Recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563Glioblastoma
NovoCure GmbH
Phase 3
741
London, Northwood, Birmingham, Cambridge, Cardiff, Edinburgh, Liverpool, Manchester
2025-02-03
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462Rheumatoid Arthritis
Immunovant Sciences GmbH
Phase 2
120
Edinburgh, London, North Shields, Wolverhampton
2025-01-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
750
Barnet, Basingstoke, Christchurch, Edinburgh, Glasgow, Hereford, Larbert, Staffordshire
2025-01-09
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
Takeda
Phase 3
396
London, Edinburgh, Glasgow
2025-01-02
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
Immunovant Sciences GmbH
Phase 2
240
Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield
2024-12-17
Active, closed
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
Laboratoires Thea
Phase 2
81
Headington, Edinburgh, London
2024-12-11
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
NCT06603844Solid Tumor
Corbus Pharmaceuticals Inc.
Phase 1/2
156
Newcastle upon Tyne, Manchester, Birkenhead, Edinburgh, Glasgow, London
2024-12-04
Rows per page Showing 51–75 of 252
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/edinburgh

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.